Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193425 · ClinicalTrials.gov registry record · Early Phase 1
Reliability of the Human Brain Connectome
A Early Phase 1 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 112
- Enrollment target
NCT02193425: Completed Early Phase 1 study, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
NCT02193425 is a Early Phase 1 study that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 112 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02193425, a Early Phase 1 study, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
Background: \- Magnetic resonance imaging (MRI) is used to investigate brain function. Researchers want to use MRI to better understand the function patterns and connections between brain regions in healthy people. This might help people with brain diseases in the future. Objectives: * To evaluate MRI methods performed twice on the same day. * To evaluate brain function using positron emission tomography (PET). Eligibility: \- Healthy volunteers at least 18 years old. Design: * Visit 1: * Participants will be screened with medical history, physical exam, and interview about drug and alcohol use and psychiatric history. * They will give blood and urine samples. Their breath will be tested for alcohol and smoking. * Visit 2: * Participants will have urine collected. They will have MRI scans, some while resting, some while doing tasks on a computer. * The MRI scanner is a metal cylinder in a strong magnetic field. Participants will lie on a table that slides in and out of the cylinder, with a coil over their head. Participants will get earplugs for loud noises. * Visit 3: * Participants will have urine collected. * A needle will guide a thin plastic tube (catheter) into each arm. The needle will be removed, leaving the catheter in the vein. * Participants will then have a PET scan. They will get the chemical 18FDG in the catheter. They will lie on a bed that slides in and out of the PET scanner, with a cap on their head. * Participants may have tests of memory, attention, concentration, and thinking. They may complete interviews, questionnaires, tests on paper or computer, and simple actions. * Participants will wear a device for 1 week between visits to measure activity and sleep.
Primary Outcome
The test-retest reproducibility of the gender and aging effects on FC measures (lFCD, C, L and S) acquired in RS and TS conditions.
Interventions
- DEVICE MRI
- DRUG F-18FDG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2015-06-08 |
| Est. Completion | 2023-05-23 |
| Phase | Early Phase 1 |
What the finished NCT02193425 record still lists
NCT02193425 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (111% higher).
The record links to 0 conditions, and to 2 interventions - of which MRI is the first listed.
NCT02193425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02193425 about?
NCT02193425 is a clinical study titled "Reliability of the Human Brain Connectome". Background: \- Magnetic resonance imaging (MRI) is used to investigate brain function. Researchers want to use MRI to better understand the function patterns and connections between brain regions in healthy people. This might help people with brain diseases in the future. Objectives: * To evaluat...
What is the current status of trial NCT02193425?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 112 participants. The study started on 2015-06-08. Estimated completion is 2023-05-23.
What interventions are being tested in trial NCT02193425?
The interventions under investigation include: MRI (DEVICE), F-18FDG (DRUG).
Who is sponsoring clinical trial NCT02193425?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02193425's enrollment target sits among peer trials
112 165th of 2000 higher than 1,836 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI